Titan Medical Inc. Ordinary Shares
TMDI
TMDI was delisted on the 9th of March, 2023.
5 hedge funds and large institutions have $6.58K invested in Titan Medical Inc. Ordinary Shares in 2023 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 7 closing their positions.
58% less funds holding
Funds holding: 12 → 5 (-7)
100% less capital invested
Capital invested by funds: $1.94M → $6.58K (-$1.94M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 7
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EL
Essex LLC
Deer Park,
Illinois
|
-$1.89M |
| 2 |
AW
Avion Wealth
The Woodlands,
Texas
|
-$26K |
| 3 |
WA
Waterford Advisors
Orchard Park,
New York
|
-$13K |
| 4 |
MCA
Magnolia Capital Advisors
Jackson,
Mississippi
|
-$2.66K |
| 5 |
MCM
MAI Capital Management
Independence,
Ohio
|
-$2.45K |
TMDI Hedge Fund Activity: Q2 2023 in Review
5 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Titan Medical Inc. Ordinary Shares (TMDI) for Q2 2023, worth a combined $6.58K — down 100% from $1.94M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of TMDI and 0 opened new positions — a net loss of 7 holders — while 1 trimmed existing stakes and 0 added.
The largest seller was Essex LLC, exiting entirely with an estimated $1.89M sold.
- 5 institutional investors held Titan Medical Inc. Ordinary Shares (TMDI) as of Q2 2023, down from 12 in Q1 2023.
- Funds reported $6.58K of Titan Medical Inc. Ordinary Shares stock for Q2 2023, down 100% quarter-over-quarter.
- 0 funds opened new Titan Medical Inc. Ordinary Shares positions in Q2 2023 and 7 closed out, a net change of -7 holders.
- The largest Titan Medical Inc. Ordinary Shares seller in Q2 2023 was Essex LLC, an estimated $1.89M sold.
Based on aggregated 13F filings for Q2 2023.